<DOC>
	<DOCNO>NCT01520103</DOCNO>
	<brief_summary>The purpose study Examination superiority combination vinorelbine mTOR Inhibitor Everolimus vs. vinorelbine monotherapy second-line treatment advance breast cancer .</brief_summary>
	<brief_title>Study Compare Vinorelbine In Combination With mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy Second-line Treatment Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 .Dated sign patient inform consent start protocol specify procedure 2 . Histologically cytologically confirm Her2/neu negative , metastatic locally advanced breast cancer , include inoperable local relapse , measurable nonmeasurable lesion palliative second line chemotherapy indicate . Antihormone palliative pretreatments count separate treatment line treatment anthracycline and/or taxanes fail suitable adequately treated operation radiotherapy 3 . An exclusive antihormone therapy indicate patient 4 . ECOG Performance Status 02 5 . Women &gt; = 18 year age 6 . Life expectancy least 12 week 7 . Adequate bone marrow , liver renal function ( accord SmPC Vinorelbine , Afinitor® ) base laboratory assessment raise within 7 day prior start study treatment : Haemoglobin &gt; = 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; = 2/mm³ Thrombocytes &gt; = 100/µl INR &gt; = 2 Serum bilirubin = &lt; 1.5x upper limit normal ( patient know Gilbert syndrome , total bilirubin = &lt; 3x upper limit normal , direct bilirubin = &lt; 1.5x upper limit normal ALT AST = &lt; 2.5x upper limit normal ( = &lt; 5x upper limit normal subject liver metastasis ) Serum cholesterol = &lt; 300 mg/dl 7.75 mmol/l triglyceride = &lt; 2.5x upper limit normal ( lipid lower drug permit ) Serum creatinin = &lt; 2x upper limit normal 8 . Documentation negative pregnancy test woman childbearing potential within 7 day prior start study . Sexual active premenopausal woman require use adequate contraception throughout duration study , except oestrogen contain contraceptive 1 . Previous treatment Vinorelbine inhibitor mTOR 2 . Treatment study medication within 28 day start treatment 3 . Patients receive prior radiotherapy ≥ 25 % bone marrow 4 . Other tumour previous 5 year exception adequately treat basal cell carcinoma skin preinvasive cervix carcinoma 5 . Simultaneous use know CYP3A4 inducer ( e.g . Phenytoin , Rifampicin ) inhibitor enzyme ( e.g . Itraconazole , Ketoconazole ) , therefore also use mistletoe , St John 's wort grapefruit juice 6 . Patients least one condition apply : Substance abuse medical , psychological social condition may interfere patient 's participation study evaluation study result judge investigator Legal incapacity limit legal capacity Subjects unable take oral medication Any condition could jeopardise safety patient compliance study judge investigator 7 . History cardiac dysfunction include one following : Myocardial infarction elevate cardiac enzyme persistent regional wall abnormality assessment LV function History document congestive heart failure ( NYHA ≥ 3 ) Documented cardiomyopathy 8 . Known HIV infection chronic hepatitis B C history hepatitis B / C 9 . Active clinically relevant infection ( &gt; grade 2 NCICTC Version 4.03 ) 10 . Clinical radiological detection CNS metastases 11 . Patients receive concomitant immunosuppressive agent chronic use corticosteroid time study entry except case outline : topical application ( e.g . rash , ) inhale spray , ( e.g . obstructive airway disease ) eye drop local injection ( e.g . intraarticular ) allow 12 . Active bleed diathesis oral antivitamin K medication ( except lowdose warfarin aspirin equivalent , long INR ≤ 2 ) 13 . Kidney function disorder require dialysis 14 . Seriously impaired liver function ( ChildPugh , class C ) 15 . Known hypersensitivity reaction Vinorelbine Everolimus 16 . Pregnant breastfeeding subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>Her2/new negative</keyword>
	<keyword>HER2 negative</keyword>
</DOC>